Full-Time

AI Data Scientist Manager

OTDS

Updated on 8/23/2026

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Bachelor's, Master's

Category
Data & Analytics (1)
Required Skills
LLM
Python
Data Science
Neural Networks
SQL
Machine Learning
AWS
Data Governance
Databricks

Get referred to Amgen

See people who can refer or advise you

Requirements
  • A Master's or Bachelor's degree in Data Science, Artificial Intelligence, Computer Science, Information Science, or a related field, with 7 to 12 years of experience.
  • Deep expertise in Generative AI, large language models, and agentic AI applications.
  • Proficiency in Python for AI solution development and scaling.
  • Strong working knowledge of SQL for enterprise data integration and analysis.
  • Experience with AWS cloud services and well-architected design principles, including AWS Bedrock.
  • Experience with OpenAI APIs and enterprise AI solution development.
  • Hands-on experience with Databricks or similar data and AI platforms.
  • Strong understanding of enterprise data ecosystems and integrated data architectures.
  • Experience with knowledge graph technologies, such as Stardog or GraphDB, and semantic data approaches.
  • Strong understanding of FAIR data principles and their enterprise application.
  • Ability to translate business strategy into scalable AI solutions and execution roadmaps.
  • Strong understanding of Responsible AI principles, governance, and compliance requirements.
  • Familiarity with AI regulatory considerations, including concepts aligned with the EU AI Act.
  • Excellent communication and stakeholder management skills across technical and business audiences.
  • Strategic thinking with the ability to align AI initiatives to enterprise transformation goals.
  • Strong analytical and problem-solving skills in complex, regulated environments.
  • Ability to manage ambiguity and drive clarity across multiple initiatives.
  • Demonstrated ability to influence without authority and build cross-functional alignment.
  • Strong customer- and product-oriented mindset.
  • High level of ownership and accountability for team outcomes and business impact.
Responsibilities
  • Ensure successful delivery of AI initiatives aligned with Operations Transformation and Digital Strategy transformation goals.
  • Design and oversee development of AI solutions using Generative AI, large language models, and agentic AI patterns.
  • Guide development of intelligent systems that combine structured and unstructured data, semantic models, and knowledge graphs.
  • Ensure transition of solutions from proof-of-concept to scalable, enterprise-ready AI products.
  • Provide technical leadership in Python-based development, SQL-based data transformation, and AI system design.
  • Collaborate with business stakeholders, product teams, architects, and engineering partners to define and deliver high-impact AI use cases.
  • Drive adoption of FAIR data principles, data-centric design, and semantic interoperability across solutions.
  • Oversee use of AWS services and cloud best practices, including AWS Bedrock, for scalable and secure architecture.
  • Guide development of AI-enabled applications leveraging OpenAI APIs and foundation model platforms.
  • Ensure effective use of Databricks and enterprise data platforms for scalable AI development and deployment.
  • Establish and enforce standards for Responsible AI, model governance, security, and compliance, including awareness of frameworks such as the EU AI Act.
  • Act as a liaison between Operations Transformation and Digital Strategy leadership and cross-functional stakeholders to align priorities and drive transformation outcomes.
  • Facilitate strategic discussions and working sessions to align on AI vision, roadmap, and value realization.
  • Stay current with advancements in AI, agentic architectures, and regulatory expectations, and guide the team in applying them effectively.
Desired Qualifications
  • Experience in pharmaceutical or life sciences environments, particularly in regulatory or operational domains.
  • Familiarity with regulatory data, submission processes, and compliance frameworks.
  • Knowledge of machine learning and deep learning techniques supporting Generative AI use cases.
  • Experience integrating data across clinical, manufacturing, quality, or regulatory systems.
  • Familiarity with FHIR, IDMP, or similar healthcare data standards.
  • Experience scaling AI solutions into enterprise products and platforms.
  • Exposure to structured content management and AI-driven content automation.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 revenue hit $10.1 billion, up 10%, and guidance rose to $39.4 billion.
  • Repatha, Evenity, and Uplizna surged 37%, 38%, and 90% in Q2 2026.
  • Amgen presented Repatha VESALIUS-CV data for ESC August 2026, expanding cardiovascular adoption.

What critics are saying

  • FDA proposed withdrawing Tavneos on April 27, 2026; EMA echoed revocation on June 26.
  • Prolia sales fell 32% in Q2 2026 as biosimilars attack Amgen’s legacy franchise.
  • Harbour BioMed won a June 2026 willful patent verdict; MariTide failure would crush growth.

What makes Amgen unique

  • Amgen’s portfolio spans cardiovascular, bone, immunology, oncology, and biosimilars.
  • MariTide targets monthly or less frequent obesity dosing, unlike weekly GLP-1 rivals.
  • Amgen runs seven research labs plus Hyderabad’s 2027 science and innovation center.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Aug 19th, 2026
Amgen surges 3.5% to $440 as healthcare stocks hit record high on strong Q2 results

Amgen shares jumped 3.5% to $440.08 on Wednesday as healthcare stocks reached record highs. The biotech company reported second-quarter revenue of $10.1 billion, up 10%, whilst GAAP earnings surged 65% to $4.37 per share. Twenty-two of Amgen's medicines posted double-digit sales growth, with seventeen products generating over $1 billion in annualised sales. Six key growth products climbed 26% and now account for nearly 70% of product revenue. The rally came as investors rotated into healthcare following excitement around Merck and Moderna's melanoma breakthrough. However, Amgen now trades at a 19% premium to its fair value estimate of $365.04, putting pressure on execution as some products like Prolia face headwinds.

Yahoo Finance
Aug 14th, 2026
Amgen and Regeneron emerge as GLP-1 investment alternatives beyond Eli Lilly and Novo Nordisk

Amgen and Regeneron could benefit from surging demand for GLP-1 drugs, which traditionally treated diabetes but now address obesity and obstructive sleep apnea. Amgen's stock is up 27% this year, with second-quarter revenue rising 10% year-over-year to $10.1 billion. The company is testing MariTide, an investigational GLP-1 medicine, in phase 3 studies for weight management and diabetes. MariTide could be administered monthly or less frequently, offering a convenience advantage over current daily or weekly treatments. Regeneron is also positioned to capitalise on the GLP-1 market expansion. Both companies present alternatives to current market leaders Eli Lilly and Novo Nordisk for investors seeking exposure to the growing GLP-1 drug category.

PR Newswire
Aug 12th, 2026
Amgen to open new science and innovation centre in Hyderabad's Genome Valley

Amgen announced plans to open a new Science and Innovation Center in Genome Valley, Hyderabad, expected to be operational in 2027. The facility will join Amgen's global Research and Development network of seven research laboratories, expanding the company's scientific capabilities. The center will bring together scientists and technologists across discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine. It will integrate experimental science with data and digital innovation to accelerate the discovery and development of medicines. "The new center in Genome Valley expands the way we integrate experimental science with data and technology across our global research capabilities," said Jay Bradner, executive vice president of Research and Development, Artificial Intelligence and Data at Amgen. The facility will complement Amgen's existing technology and innovation site in Hyderabad.

Yahoo Finance
Aug 9th, 2026
Amgen fair value rises to $372 after Q2 beat sparks analyst target hikes to $450

Amgen's modeled fair value has risen from $352.23 to $371.93 per share following strong Q2 results and updated analyst targets. Several firms, including Scotiabank, TD Cowen, BMO Capital, and Oppenheimer, lifted price targets to around $450, citing earnings revisions and a diversified product portfolio. Bernstein noted a 6.8% revenue beat and 12.5% non-GAAP EPS beat in Q2, with raised full-year guidance driven by portfolio-wide execution. Strength came from products including Repatha, Tezspire, Uplizna, Evenity, and Imdelltra. However, Wells Fargo and Citi maintain cautious stances with Equal Weight and Neutral ratings, suggesting current performance may already be priced in. BofA kept its Underperform rating, describing 2026 as focused on execution ahead of key 2027 readouts.

Yahoo Finance
Aug 5th, 2026
Amgen beats Q2 forecast with $10.05B revenue, raises 2026 outlook despite obesity drug setback

Amgen reported second-quarter revenue of $10.05 billion, up 9% year on year, beating Wall Street expectations. Adjusted earnings reached $6.29 per share, surpassing the $5.62 consensus estimate. The biotech firm raised its full-year 2026 outlook, increasing expected revenue to $38.2 billion-$39.4 billion from $37.0 billion-$38.4 billion. Adjusted earnings guidance rose to $22.30-$23.50 per share. Repatha sales surged 37% to $953 million, whilst Evenity jumped 38% to $714 million. Rare-disease therapy Uplizna saw roughly 90% growth. These gains offset a 32% decline in Prolia sales due to biosimilar competition. Amgen discontinued obesity candidate AMG 513 but continues developing MariTide, with Phase 3 data expected in 2027. The stock trades at $406.17, approximately 14.75% above its estimated fair value.